ArticleThe American journal of pathology1996
SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Secreted Protein Acidic and Rich in Cysteine as a Molecular Physiological and Pathological Biomarker.Biomolecules · 2021Review
- SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties.Journal of neuroinflammation · 2016Article
- Albumin-based drug delivery: harnessing nature to cure disease.Molecular and cellular therapies · 2016Review
- Correlation of secreted protein acidic and rich in cysteine with diabetic nephropathy.International journal of clinical and experimental medicine · 2015Article
- The Function of SPARC as a Mediator of Fibrosis.The open rheumatology journal · 2012Article
- SPARC is expressed in scars of the Tenon's capsule and mediates scarring properties of human Tenon's fibroblasts in vitro.Molecular vision · 2011Article
- SPARC accelerates disease progression in experimental crescentic glomerulonephritis.The American journal of pathology · 2009Article
- Myocilin promotes substrate adhesion, spreading and formation of focal contacts in podocytes and mesangial cells.Histochemistry and cell biology · 2009Article
- Article
- Overexpression of apolipoprotein J in human fibroblasts protects against cytotoxicity and premature senescence induced by ethanol and tert-butylhydroperoxide.Cell stress & chaperones · 2002Article
- Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis.The American journal of pathology · 2001Article
- Reduced expression of laminin alpha 3 and alpha 5 chains in non-small cell lung cancers.Japanese journal of cancer research : Gann · 2001Article
- Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction.Journal of thrombosis and thrombolysis · 2000Article
- Type IV collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis via beta(1) integrin-mediated survival signals.The American journal of pathology · 1999Article
- Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation.Molecular biology of the cell · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Mesangial cell proliferation is a characteristic feature of many glomerular diseases and often precedes extracellular matrix expansion and glomerulosclerosis. This study provides the first evidence that SPARC (secreted protein acidic and rich in cysteine) could be an endogenous factor mediating resolution of experimental mesangial proliferative nephritis in the rat. SPARC is a platelet-derived-growth-factor-binding glycoprotein that inhibits proliferation of endothelial cells and fibroblasts. We now show that SPARC is synthesized by mesangial cells in culture and that SPARC mRNA levels are increased by platelet-derived growth factor and basic fibroblast growth factor. Recombinant SPARC or the synthetic SPARC peptide 2.1 inhibited platelet-derived-growth-factor-induced mesangial cell DNA synthesis in vitro. In a model of experimental mesangioproliferative glomerulonephritis, SPARC mRNA was increased 5-fold by day 7 and was identified in the mesangium by in situ hybridization. Similarly, SPARC was increased in glomerular mesangial cells and visceral epithelial cells by day 5 and reached maximal expression levels by day 7. Mesangial cell proliferation increased by 36-fold on day 5 and decreased abruptly on day 7. Maximal expression of SPARC was correlated with the resolution of mesangial cell proliferation. We propose that SPARC functions in part as an endogenous inhibitor of platelet-derived-growth-factor-mediated mesangial cell proliferation in glomerulonephritis and that it could account for the resolution of cellular proliferation in this disease.
Indexed as
Identifiers
8644857PMC1861539W259476979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.